Post-Market Clinical Follow-up Performance and Safety Study of Etermis 3 and 4 in the Face

CompletedOBSERVATIONAL
Enrollment

154

Participants

Timeline

Start Date

June 1, 2016

Primary Completion Date

December 27, 2017

Study Completion Date

December 27, 2017

Conditions
Correction of Facial Wrinkles/FoldsFacial Volume Enhancement
Interventions
DEVICE

Etermis 3

Cross-linked hyaluronic dermal filler. Treatment and follow-up according to standard of care and instruction of use for filling facial moderate wrinkles (marionette lines) and/or to increase lip volume

DEVICE

Etermis 4

Cross-linked hyaluronic dermal filler. Treatment and follow-up according to standard of care and instruction of use for filling deep and severe volume loss (nasolabial folds and/or marionette lines) and/or to increase lip volume

Trial Locations (6)

14467

Merz Investigational Site #0490362, Potsdam

20146

Merz Investigational Site #0490095, Hamburg

22609

Merz Investigational Site #0490345, Hamburg

34121

Merz Investigational Site #0490309, Kassel

64283

Merz Investigational Site #0490099, Darmstadt

80333

Merz Investigational Site #0490368, München

Sponsors
All Listed Sponsors
lead

Merz Pharmaceuticals GmbH

INDUSTRY

NCT04210258 - Post-Market Clinical Follow-up Performance and Safety Study of Etermis 3 and 4 in the Face | Biotech Hunter | Biotech Hunter